JESSICA MATTISON: Open Payments
NPI 1467011445 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 22 payments from 15 companies in 2025. Trend: 2023 $632 · 2024 $363 · 2025 $468
Food & beverage: $443Education: $26
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $102 |
| Merck Sharp & Dohme LLC | 3 | $66 |
| Novartis Pharmaceuticals Corporation | 3 | $60 |
| PharmaEssentia USA Corporation | 1 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| Genmab U.S., Inc. | 1 | $21 |
Products named: EPKINLY, SCEMBLIX, VENCLEXTA, KEYTRUDA, BESREMI, WELIREG, Onivyde, Lenvima.
Industry payments across NE — which companies pay providers there.
